Skip to content

Study · Not a test of the peptide alone · 2014

2 results

A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes.

Ramkissoon CM, Aufderheide B, Bequette BW, Palerm CC

Journal of diabetes science and technology9 Feb 2014Cited by 6 (Europe PMC)

PMID24876617 (opens in a new tab)PMCIDPMC4455443 (opens in a new tab)DOI10.1177/1932296813517323 (opens in a new tab)PepBankPUB-24876617
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 01Computer modelNot a test of Pramlintide (Symlin) aloneIn silicoOther

    In a computational model, subcutaneous pramlintide pharmacokinetic root mean square errors ranged from 1.98 to 10.66 pmol/L.

    In plain wordsComputer modelling produced pramlintide pharmacokinetic errors of 1.98 to 10.66 pmol/L.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicablePharmacokinetic model RMSE
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    PK RMSE
    1.98 to 10.66 pmol/L
    subcutaneous pramlintide model

    Source sentences

    Summary
    SC pramlintide PK root mean square error values range from 1.98 to 10.66 pmol/L.
    2 context sentences
    Summary · context
    A model of subcutaneous (SC) pramlintide pharmacokinetics (PK) was developed by revising an intravenous (IV) pramlintide PK model and adapting SC insulin PK from a glucose-insulin model.
    Summary · context
    The model was fit and validated using 27 data sets, which included placebo, PK, and PD data.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  2. 02Computer modelNot a test of Pramlintide (Symlin) aloneIn silicoOther

    In a computational model, pramlintide pharmacodynamic root mean square errors ranged from 10.48 to 42.76 mg/dL.

    In plain wordsComputer modelling produced pramlintide pharmacodynamic errors of 10.48 to 42.76 mg/dL.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicablePharmacodynamic model RMSE
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    PD RMSE
    10.48 to 42.76 mg/dL
    pramlintide model

    Source sentences

    Summary
    Pramlintide PD RMSE values range from 10.48 to 42.76 mg/dL.
    2 context sentences
    Summary · context
    A model of subcutaneous (SC) pramlintide pharmacokinetics (PK) was developed by revising an intravenous (IV) pramlintide PK model and adapting SC insulin PK from a glucose-insulin model.
    Summary · context
    The model was fit and validated using 27 data sets, which included placebo, PK, and PD data.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.